SurGenTec Receives Novel FDA Clearance for ION-L™ Lumbar Facet Fixation System

SurGenTec has received US Food and Drug Administration (FDA) clearance for its ION-L™ Lumbar Facet Fixation System, a minimally invasive device developed to treat patients with degenerative disc disease affecting the lumbar spine. 

The system is indicated for use in skeletally mature patients with conditions between the L3 and S1 vertebrae who have not responded to conservative treatment.

ION-L™ has been designed to support posterior lumbar facet fixation while reducing the surgical footprint. The device is implanted through a posterior approach and spans the facet joint to provide stabilisation during spinal fusion.

Its design enables controlled insertion while minimising disruption to surrounding tissues, supporting a less invasive surgical procedure compared with conventional fixation methods.
The system incorporates several features intended to improve fusion outcomes, including a zero-profile implant design, structures that support bone graft integration and a specialised surface technology that promotes bone growth and osseointegration. 

The implant is also engineered to maintain neutral joint positioning and reduce the risk of implant displacement following placement.

FDA clearance was supported by findings from an independent multicentre clinical study conducted with Institutional Review Board approval. The study evaluated the long-term safety and effectiveness of the system in patients with complex spinal conditions. 

Independent radiological assessments confirmed successful fusion outcomes, and no device-related adverse events were reported during the study.

ION-L™ is supplied with sterile, single-use surgical instruments and ready-to-use implants, helping simplify surgical workflows while reducing instrument reprocessing requirements. 

The system is now commercially available in the United States, expanding SurGenTec's portfolio of minimally invasive spinal fixation technologies.